Digital Health Companies Struggle in 2024 Amid Post-Covid Adjustments
The year 2024 has been a tough one for digital health companies, marking a stark contrast to the boom times of the Covid era. While the...
The year 2024 has been a tough one for digital health companies, marking a stark contrast to the boom times of the Covid era. While the...
On Tuesday, genetic testing company 23andMe reported a revenue decline for its latest fiscal quarter, following its announcement of significant workforce reductions and the closure of...
Anne Wojcicki, CEO of 23andMe, has submitted a proposal to take the genetic testing company private, as its stock price remains below $1. In a filing...